Paolo Macor

The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma

Recently, we developed AT101, an IgM-class mouse monoclonal antibody directed against glypican-1 (GPC1), a proteoglycan considered as useful target for pancreatic adenocarcinoma (PDAC) treatment being specifically and highly expressed on PDAC cell surface. Here, we proposed AT101...